Hepatitis B virus (HBV) reactivation, a well-known complication in immunosuppressed patients, can give rise to acute hepatitis and even fatal fulminant hepatitis. Three Japanese males with non-Hodgkin's lymphoma (NHL) who were carriers of HBV received high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT). To prevent HBV reactivation, all received oral lamivudine (150 mg/day), a nucleoside analogue, at the start of chemotherapy. All were treated at full-dose intensity, including corticosteroids, without modification of treatment regimens. All three patients completed the total course of chemotherapy and PBSCT, with no signs of HBV reactivation. Peripheral blood stem cell (PBSC) harvests and hematological recoveries after transplantation were not affected by lamivudine, which was continued for at least 16 weeks after transplantation. HBV-DNA and DNA polymerase levels remained negative/normal after discontinuation of lamivudine. Lamivudine effectively inhibits HBV replication and has few serious adverse effects, particularly those related to hematopoiesis. Thus, prophylactic use of lamivudine from initiation of chemotherapy deserves consideration in the treatment of HBV carriers who require immunosuppressive chemotherapy, and may prevent HBV reactivation. Bone Marrow Transplantation (2001) 27, 433-436. Keywords: non-Hodgkin's lymphoma; hepatitis B; lamivudine; peripheral blood stem cell transplantation (PBSCT) Recent studies have shown that an improved prognosis or even cure can be achieved by high-dose chemotherapy followed by stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma (NHL).
hepatitis B virus (HBV) carriers with NHL may be given reduced doses of chemotherapy, or this may be discontinued because of development of hepatitis or fatal fulminant hepatitis as a result of HBV reactivation. [2] [3] [4] [5] [6] [7] Nucleoside analogues, such as famciclovir and lamivudine suppress HBV replication and have few serious adverse effects. 8, 9 Lamivudine has enabled completion of chemotherapy and PBSCT after hepatitis flare-up in HBV carriers. 10, 11 To our knowledge, prophylactic use of lamivudine from initiation of chemotherapy has not been reported. We treated three males with NHL who were HBV carriers with lamivudine which was started at the commencement of chemotherapy. Patient characteristics are summarized in Tables 1 and 2 .
Methods
Serum hepatitis B surface antigen (HBsAg), hepatitis e antigen (HBeAg), and hepatitis e antibody (HBeAb) were tested, using an enzyme immunoassay. HBV-DNA polymerase was determined by radioassay using 3 H-thymidine triphosphate substrate (normal Ͻ30 c.p.m.).
12 Serum HBV-DNA was measured by a branched DNA probe assay. 13 According to the manufacturer, sensitivity was 0.7 megaequivalents per milliliter. Mutated HBV was detected using PCR-RFLP.
14 Serum HBV-DNA and DNA polymerase levels were monitored weekly during lamivudine treatment, then every 2 weeks after its discontinuation.
Prior to starting lamivudine treatment, written informed consent was obtained and the Committee of Hokkaido University School of Medicine for the Protection of Human Subjects gave approval for the study.
Case reports

Case 1
A 44-year-old Japanese male was diagnosed with follicular large B cell type NHL. He was also a HBV carrier with no active hepatitis. HBV-DNA polymerase levels were 16
Bone Marrow Transplantation c.p.m., and serum HBV-DNA was undetectable. Clonal analysis of HBV revealed a 100% precore mutant. Liver biopsy revealed mild fatty changes but no signs of active hepatitis and no involvement by lymphoma. For induction, CHOP therapy and G-CSF were administered. 15 We prescribed six mega-units of interferon-␣ (IFN-␣) three times a week with the chemotherapy to prevent HBV reactivation. 16 Complete remission (CR) was achieved but interstitial pneumonia (IP) developed after three cycles of CHOP. However, recovery was rapid while he was receiving prednisolone 80 mg daily. IFN-␣ was withdrawn as the possible cause of the IP. Lamivudine (marketed as Epivir in Japan; Glaxo-Wellcome (Tokyo, Japan), 150 mg/day), a nucleoside analogue, was then prescribed as prophylaxis for hepatitis. Next, three cycles of the VIP regimen 17 were given. After the first cycle of VIP, peripheral blood stem cells (PBSC) were harvested. High-dose chemotherapy (MCVC regimen 18 ) was then given, with PBSCT support. During the high-dose chemotherapy, his aminotransferase levels rose, but HBV-DNA and HBV-DNA polymerase levels remained within normal range. Lamivudine was continued for 40 weeks after the PBSCT. Hepatitis did not develop after discontinuation of lamivudine. He has now been in CR for 27 months following PBSCT.
Case 2
A 49-year-old Japanese male was diagnosed with diffuse large B cell NHL. Virological studies revealed HBV carrier status. The HBV-DNA polymerase level was 14 c.p.m., and serum HBV-DNA was undetectable. All liver function tests were normal, including aminotransferase levels. Clonal analysis for HBV revealed a 100% precore mutant. Liver biopsy revealed no evidence of active hepatitis and no involvement by lymphoma. CHOP therapy was administered initially. We prescribed lamivudine (150 mg/day) with the chemotherapy. After six cycles of CHOP therapy and radiotherapy to the left cervical lymph nodes, bone scintigraphy showed abnormal uptake in the second lumbar vertebra (L2). A bone biopsy of L2 revealed NHL. Three cycles of VIP were started. After the first cycle, PBSC were harvested. After radiotherapy to the lumbar vertebrae (L2-L4), the MCVC regimen was given with PBSCT support. During treatment, his HBV-DNA polymerase was slightly elevated, but aminotransferase and HBV-DNA levels were within normal ranges. Lamivudine was continued for 16 weeks after PBSCT. Hepatitis did not developed after discontinuation of the lamivudine. Currently, he is in CR 10 months after transplantation.
Case 3
A 51-year-old Japanese male presented with a mediastinal tumor 50 mm in diameter and surgical resection was undertaken. Histology revealed lymphoblastic T cell-type NHL. Computed tomography scanning revealed no other lymph node enlargement. Virological examination revealed HBV carrier status. His ␥-GTP was elevated to 128 IU/l, but all other liver function tests were within the normal ranges. The HBV-DNA polymerase level was 34 c.p.m., and HBV-DNA was undetectable. Clonal analysis of HBV revealed a 90% precore mutant. Biopsy revealed a fatty liver but no evidence of active hepatitis and no involvement by lymphoma. Three months after resection of the tumor, six cycles of CHOP therapy were begun. Lamivudine (150 mg/day) was given with the chemotherapy. After the fourth cycle of CHOP, PBSC were harvested. After six cycles of CHOP, the MCVC regimen was given, with PBSCT support. During this treatment, the HBV-DNA polymerase was transiently elevated, but HBV-DNA was undetectable. Lamivudine was continued for 16 weeks after the PBSCT. Hepatitis did not develop after discontinuation of the lamivudine. Currently, he is in CR 11 months after transplantation.
Discussion
Occurrence of active hepatitis after chemotherapy for hematological malignancies can be a serious complication experienced by HBV carriers. Some patients have succumbed to fulminant hepatitis, even though abnormalities of liver function before chemotherapy were never evident. [2] [3] [4] [5] [6] [7] Half the patients receiving chemotherapy who are also chronic hepatitis B carriers may develop hepatitis B-related complications, and liver-related mortality rates are 5-20%. [3] [4] [5] [6] [7] Hepatitis B-related complications may cause delays or modifications of therapy, and hence the chance of cure is reduced.
Mechanisms of hepatitis development after chemotherapy are as follows: HBV replication is enhanced during immunosuppressive therapy, and cytotoxic T cells destroy HBV-infected hepatocytes after recovery of host immunity. 4 Therefore, inhibition of HBV replication during the period of immunosuppression is important in preventing possible development of hepatitis.
There is no known reliable way of predicting the severity of hepatitis B reactivation after chemotherapy. Acute hepatic injury and fulminant hepatitis are more common in patients treated with more intensive regimens and in patients who have seroconverted (HBeAg negative, HBeAb positive), possibly due to the presence of mutated HBV. 6, 19, 20 This being the case, our patients were considered to be at risk for development of hepatitis.
Several reports suggest that corticosteroids are important predisposing factors for HBV reactivation and these are sometimes therefore not prescribed for chronic hepatitis B carriers. 21, 22 However, almost all NHL chemotherapy regimens contain corticosteroids, and suboptimal cytotoxic therapy may reduce the likelihood of remission. Furthermore, hepatitis can develop even in those on steroid-free chemotherapy. 5 Our patients were therefore treated at fulldose intensity, including corticosteroids, without modification of the chemotherapy regimens. 1 Total doses of corticosteroids (prednisolone) during the clinical courses were 4260 mg, 2190 mg, and 2940 mg, for patients 1, 2 and 3, respectively. Our data suggest that prevention of HBV replication by an antiviral drug during immunosuppression may make it feasible for HBV carriers to continue with the usual chemotherapy, even when corticosteroids are included.
To date few drugs seem to be effective in suppressing HBV replication, including interferon, famciclovir, and
Bone Marrow Transplantation lamivudine. Interferon has adverse effects such as causing high fevers, induction of pancytopenia, and interstitial pneumonia. Some inhibitors of RNA virus reverse transcriptase may suppress HBV-DNA replication and among them, famciclovir and lamivudine have potent antiviral activity against HBV. 8, 9 There is a report to suggest that prophylactic use of famciclovir may result in a significant decrease in the incidence and severity of HBV reactivation after bone marrow transplantation. 23 Lamivudine was found to be superior to famciclovir in terms of HBV-DNA reduction and response to treatment of subjects with chronic hepatitis B infection. 24 Lamivudine directly suppresses HBV replication by incorporation of its monophosphate form into DNA by HBV polymerase, the result being chain termination. 9 Dienstag et al 9 reported that HBV-DNA levels were undetectable in 100% of patients with chronic hepatitis B treated with over 100 mg per day lamivudine, and adverse effects such as transient, asymptomatic elevation of amylase, lipase and creatine kinase levels were minor.
Lamivudine was found to be effective in the management of HBV reactivation after chemotherapy and stem cell transplantation, 10, 11 when lamivudine was prescribed after a flare-up of the hepatitis had occurred. However, for more severe cases, it may be too late for the drug to be effective because there is already a high viral load in the liver at this stage. 20 HBV reactivation has usually been observed after the first two cycles of chemotherapy, 2,10,11 which suggests that lamivudine should be introduced at initiation of chemotherapy to prevent early HBV reactivation. To our knowledge, such prophylactic use of lamivudine has never been documented. Our three patients completed their entire chemotherapy programmes and PBSCT, with no signs of HBV reactivation. We found no adverse effects of lamivudine. Peripheral blood stem cells harvests and hematological recoveries after transplantation were not affected by lamivudine.
The optimum duration of lamivudine therapy has yet to be established. As reactivation of HBV can occur after it has been discontinued, 25 careful monitoring should be undertaken. On the other hand, prolonged use of lamivudine can lead to development of resistance, as a result of virus mutation. HBV-DNA and DNA polymerase levels remained negative/normal after the discontinuation of lamivudine in our patients.
Either a large series of patients with different levels of HBV replication at the start of chemotherapy, or a radomized trial with prophylactic vs interventional lamivudine is required. Further prospective studies are being planned to define the best approach to manage HBsAg-positive patients receiving chemotherapy or PBSCT.
